



Financial Statements

Minnesota Ovarian Cancer Alliance

Minneapolis, Minnesota

For the years ended December 31, 2022 and 2021



Edina Office

5201 Eden Avenue, Ste 250
Edina, MN 55436
P 952.835.9090

Mankato Office

100 Warren Street, Ste 600
Mankato, MN 56001
P 507.625.2727

Scottsdale Office

14500 N Northsight Blvd, Ste 233
Scottsdale, AZ 85260
P 480.864.5579

Minnesota Ovarian Cancer Alliance
Table of Contents
December 31, 2022 and 2021

	<u>Page No.</u>
Independent Auditor's Report	3
Financial Statements	
Statements of Financial Position	6
Statements of Activities	7
Statements of Functional Expenses	9
Statements of Cash Flows	11
Notes to the Financial Statements	12

INDEPENDENT AUDITOR'S REPORT

Board of Directors
Minnesota Ovarian Cancer Alliance
Minneapolis, Minnesota

Opinion

We have audited the accompanying financial statements of the Minnesota Ovarian Cancer Alliance (the Organization), which comprise the statement of financial position as of December 31, 2022, and the related statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements (collectively, the financial statements).

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Organization as of December 31, 2022, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Organization and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Prior Period Financial Statements

The financial statements of the Organization as of December 31, 2021 were audited by other auditors, whose report dated April 25, 2022, expressed an unmodified opinion on those statements.

Abdo
Minneapolis, Minnesota
April 17, 2023



FINANCIAL STATEMENTS

Minnesota Ovarian Cancer Alliance
Statements of Financial Position
December 31, 2022 and 2021

	2022	2021
Assets		
Current Assets		
Cash and cash equivalents	\$ 876,089	\$ 1,278,105
Accounts receivable	3,005	2,500
Pledges receivable, current	10,000	-
Prepaid expenses	20,488	39,952
Inventory	4,945	4,384
Total Current Assets	914,527	1,324,941
Noncurrent Assets		
Property and Equipment		
Building and improvements	358,084	354,504
Land	37,404	37,404
Office equipment	48,060	53,318
Website	10,500	10,500
Total Property and Equipment	454,048	455,726
Less: Accumulated Depreciation	(184,861)	(177,794)
Total Property and Equipment, Net	269,187	277,932
Other Assets		
Pledges receivable, noncurrent	10,000	-
Investments	371,456	443,688
Total Other Assets	381,456	443,688
Total Assets	\$ 1,565,170	\$ 2,046,561
Liabilities		
Current Liabilities		
Accounts payable	\$ 11,623	\$ 13,951
Accrued expenses	26,642	28,830
Grants and awards payable	633,500	560,500
Total Liabilities	671,765	603,281
Net Assets		
Without donor restrictions	837,504	1,399,811
With donor restrictions	55,901	43,469
Total Net Assets	893,405	1,443,280
Total Liabilities and Net Assets	\$ 1,565,170	\$ 2,046,561

See Independent Auditor's Report and Notes to the Combined Financial Statements.

Minnesota Ovarian Cancer Alliance
Statements of Activities
For the Years Ended December 31, 2022 and 2021

	2022		Total
	Without Donor Restrictions	With Donor Restrictions	
Revenue and Support			
Contributions	\$ 1,053,671	\$ 17,937	\$ 1,071,608
In-kind contributions	92,903	-	92,903
Special event revenue, net of expenses of \$97,972	102,511	-	102,511
Investment loss	(66,503)	-	(66,503)
Total Revenue and Support	<u>1,182,582</u>	<u>17,937</u>	<u>1,200,519</u>
Net assets released from restriction	<u>5,505</u>	<u>(5,505)</u>	<u>-</u>
Total Revenue and Support	<u>1,188,087</u>	<u>12,432</u>	<u>1,200,519</u>
Expenses			
Program services	1,541,843	-	1,541,843
Management and general	104,291	-	104,291
Fundraising	104,260	-	104,260
Total Expenses	<u>1,750,394</u>	<u>-</u>	<u>1,750,394</u>
Change in Net Assets	(562,307)	12,432	(549,875)
Beginning Net Assets	<u>1,399,811</u>	<u>43,469</u>	<u>1,443,280</u>
Ending Net Assets	<u>\$ 837,504</u>	<u>\$ 55,901</u>	<u>\$ 893,405</u>

See Independent Auditor's Report and Notes to the Combined Financial Statements.

Minnesota Ovarian Cancer Alliance
Statements of Activities (Continued)
For the Years Ended December 31, 2022 and 2021

	2021		
	Without Donor Restrictions	With Donor Restrictions	Total
Revenue and Support			
Contributions	\$ 974,903	\$ 4,463	\$ 979,366
In-kind contributions	39,034	-	39,034
Government grants	82,432	-	82,432
Special event revenue, net of expenses of \$55,237	383,408	-	383,408
Investment income	65,388	-	65,388
Other income	35,738	-	35,738
Total Revenue and Support	<u>1,580,903</u>	<u>4,463</u>	<u>1,585,366</u>
Net Assets Released from Restrictions	<u>10,672</u>	<u>(10,672)</u>	<u>-</u>
Total Revenue and Support	<u>1,591,575</u>	<u>(6,209)</u>	<u>1,585,366</u>
Expenses			
Program services	1,232,590	-	1,232,590
Management and general	97,650	-	97,650
Fundraising	63,443	-	63,443
Total Expenses	<u>1,393,683</u>	<u>-</u>	<u>1,393,683</u>
Change in Net Assets	197,892	(6,209)	191,683
Beginning Net Assets	<u>1,201,919</u>	<u>49,678</u>	<u>1,251,597</u>
Ending Net Assets	<u>\$ 1,399,811</u>	<u>\$ 43,469</u>	<u>\$ 1,443,280</u>

See Independent Auditor's Report and Notes to the Combined Financial Statements.

Minnesota Ovarian Cancer Alliance
Statements of Functional Expenses
For the Year Ended December 31, 2022

	Program Services					Total Program Services	Management and General	Fundraising	Total
	Awareness and Outreach	Medical Education	Patient and Caregiver Support	Research	Any Mountain				
Salaries and Benefits									
Wages	\$ 121,547	\$ 35,822	\$ 130,585	\$ 50,732	\$ -	\$ 338,686	\$ 62,940	\$ 27,406	\$ 429,032
Benefits and payroll tax	19,725	6,412	22,059	8,091	-	56,287	9,189	4,467	69,943
Total Salaries and Benefits	141,272	42,234	152,644	58,823	-	394,973	72,129	31,873	498,975
Expenses									
Grants, awards and scholarships	-	5,505	32,500	999,246	-	1,037,251	-	-	1,037,251
Special event- direct benefits	-	-	-	-	-	-	-	97,972	97,972
In-kind expenses	2,440	1,739	1,739	2,289	-	8,207	4,699	25,882	38,788
Occupancy	7,555	2,218	8,117	3,116	-	21,006	4,203	1,694	26,903
Software fees	6,463	334	3,508	660	-	10,965	731	14,317	26,013
Professional fees	-	-	-	9,720	-	9,720	13,787	-	23,507
Depreciation	5,155	1,512	5,538	2,122	-	14,327	2,714	1,154	18,195
Printing, design and incentives	2,566	84	4,999	316	-	7,965	649	9,150	17,764
Miscellaneous	2,671	-	-	-	295	2,966	229	8,870	12,065
Postage, shipping and delivery	2,573	67	262	182	-	3,084	318	5,431	8,833
Telephone	2,396	703	2,573	987	-	6,659	1,264	537	8,460
Event location	-	-	5,322	-	1,686	7,008	-	-	7,008
Supplies	1,385	298	2,193	417	68	4,361	1,103	835	6,299
Taxes, licenses and bank fees	1,604	295	1,081	413	-	3,393	642	1,177	5,212
Insurance	1,191	349	1,280	490	-	3,310	1,622	267	5,199
Awareness and outreach, LEWK	1,498	-	-	-	3,407	4,905	-	-	4,905
Meeting, conferences and travel	482	266	6	90	48	892	55	2,853	3,800
Equipment rental and maintenance	272	79	291	112	-	754	146	61	961
Media, advertising and promotions	97	-	-	-	-	97	-	159	256
Total Expenses	179,620	55,683	222,053	1,078,983	5,504	1,541,843	104,291	202,232	1,848,366
Less: Expenses netted against revenue on the statement of activities: Direct Benefit Expense	-	-	-	-	-	-	-	(97,972)	(97,972)
Total Expenses	\$ 179,620	\$ 55,683	\$ 222,053	\$ 1,078,983	\$ 5,504	\$ 1,541,843	\$ 104,291	\$ 104,260	\$ 1,750,394

See Independent Auditor's Report and Notes to the Combined Financial Statements.

Minnesota Ovarian Cancer Alliance
Statements of Functional Expenses (Continued)
For the Year Ended December 31, 2021

	Program Services				Total Program Services	Management and General	Fundraising	Total
	Awareness and Outreach	Medical Education	Patient and Caregiver Support	Research				
Salaries and Benefits								
Wages	\$ 106,740	\$ 31,386	\$ 113,639	\$ 47,047	\$ 298,812	\$ 59,497	\$ 24,460	\$ 382,769
Benefits and payroll tax	17,744	5,862	19,822	7,631	51,059	8,692	4,066	63,817
Total Salaries and Benefits	<u>124,484</u>	<u>37,248</u>	<u>133,461</u>	<u>54,678</u>	<u>349,871</u>	<u>68,189</u>	<u>28,526</u>	<u>446,586</u>
Expenses								
Grants, awards and scholarships	-	7,500	29,200	715,929	752,629	-	-	752,629
Special event - direct benefits	-	-	-	-	-	-	55,237	55,237
Meeting, conferences and travel	709	-	78	25,286	26,073	228	149	26,450
In-kind expenses	4,345	3,325	3,435	4,375	15,480	2,100	5,170	22,750
Professional fees	-	-	-	9,000	9,000	12,542	-	21,542
Occupancy	5,698	1,717	6,052	2,645	16,112	3,341	1,312	20,765
Depreciation	5,270	1,572	5,595	2,398	14,835	2,954	1,214	19,003
Software fees	5,809	306	2,979	577	9,671	689	4,930	15,290
Telephone	3,869	1,162	4,113	1,769	10,913	2,175	886	13,974
Miscellaneous	5,599	-	-	1,105	6,704	-	6,630	13,334
Other event expenses	485	146	516	221	1,368	-	10,772	12,140
Insurance	1,105	332	1,175	507	3,119	1,788	253	5,160
Media, advertising and promotions	1,304	-	3,297	-	4,601	466	92	5,159
Postage, shipping and delivery	2,389	56	214	107	2,766	213	2,098	5,077
Supplies	1,461	353	1,298	542	3,654	825	410	4,889
Taxes, licenses and bank fees	1,360	288	1,022	440	3,110	820	868	4,798
Event location	-	-	2,050	-	2,050	270	110	2,430
Employee training	-	-	-	-	-	961	-	961
Printing, design and incentives	443	32	111	48	634	89	23	746
Total Expenses	<u>164,330</u>	<u>54,037</u>	<u>194,596</u>	<u>819,627</u>	<u>1,232,590</u>	<u>97,650</u>	<u>118,680</u>	<u>1,448,920</u>
Less: Expenses netted against revenue on the statement of activities:								
Direct Benefit Expenses	-	-	-	-	-	-	(55,237)	(55,237)
Total Expenses	<u>\$ 164,330</u>	<u>\$ 54,037</u>	<u>\$ 194,596</u>	<u>\$ 819,627</u>	<u>\$ 1,232,590</u>	<u>\$ 97,650</u>	<u>\$ 63,443</u>	<u>\$ 1,393,683</u>

See Independent Auditor's Report and Notes to the Combined Financial Statements.

Minnesota Ovarian Cancer Alliance
Statements of Cash Flows
For the Years Ended December 31, 2022 and 2021

	2022	2021
Cash Flows from Operating Activities		
Change in net assets	\$ (549,875)	\$ 191,683
Adjustments to Reconcile Change in Net Assets to Net Cash		
Provided (Used) by Operating Activities		
Depreciation	18,195	19,003
Realized and unrealized loss (gain) on investments	73,912	(58,393)
(Increase) decrease in operating assets:		
Accounts receivable	(505)	24,500
Pledges receivable	(20,000)	-
Prepaid expenses	19,464	(5,921)
Inventory	(561)	2,184
Increase (decrease) in liabilities		
Accounts payable	(2,328)	11,831
Accrued expenses	(2,188)	861
Grants and awards payable	73,000	182,500
Net Cash Provided (Used) by Operating Activities	(390,886)	368,248
Cash Flows From Investing Activities		
Purchase of investments	(1,680)	(15,974)
Proceeds from sale of investments	-	7,500
Purchase of equipment	(9,450)	-
Net Cash Used by Investing Activities	(11,130)	(8,474)
Net Change in Cash and Cash Equivalents	(402,016)	359,774
Cash and Cash Equivalents- Beginning of year	1,278,105	918,331
Cash and Cash Equivalents- End of year	\$ 876,089	\$ 1,278,105
Supplemental Disclosure of Non-cash Transactions		
Disposal of fully depreciated fixed assets	\$ 11,127	\$ -

See Independent Auditor's Report and Notes to the Combined Financial Statements.

Minnesota Ovarian Cancer Alliance
Notes to the Financial Statements
December 31, 2022 and 2021

Note 1: Summary of Significant Accounting Policies

A. Nature of Organization

The Minnesota Ovarian Cancer Alliance (the Organization or MOCA) is a statewide nonprofit organization dedicated to raising awareness, providing support to women and families impacted by the disease, and funding the research needed to detect ovarian cancer early and treat it properly. The Organization also works to educate the Minnesota medical community about the symptoms of ovarian cancer, appropriate diagnosis and related issues of ovarian cancer. The Organization is made up of a network of more than 1,000 survivors and 50,000 supporters with a full range of programs encompassing education to the public and healthcare professionals, support groups, and programing research. The Organization has awarded over \$10 million to research projects for ovarian cancer research.

The organization operates the following programs:

Awareness and Outreach

MOCA increased awareness about ovarian cancer and support for survivors through various public events in 2022 such as HOM Teal Strides for Ovarian Cancer, Tie it Teal with the Twins Ovarian Cancer Awareness Night, Ovarian Cancer Awareness Event at a Minnesota Wild Game, Unleash the She 5k 10k Race, MOCA Lights the Night initiative (20 landmarks lit throughout Minnesota and beyond), 21 awareness initiatives, and four educational events including three Living Well meetings and one Lunch and Learn meeting. MOCA has a strong media presence and placed 32 unique stories about ovarian cancer on all local TV stations, a national news organization and in several print outlets throughout Minnesota. MOCA events and media stories include information about ovarian cancer, its impact on women, families and the community - and ways to improve survival. MOCA produces a monthly MOCA Messenger newsletter and regular updates via email. Additionally, MOCA raises awareness about ovarian cancer through our social media channels including Facebook, Twitter, Instagram, LinkedIn and YouTube.

Medical Education

MOCA recognizes the critical role health care providers play in recognizing the symptoms of ovarian cancer and diagnosing the disease to improve patient survival. A full-time staff person is designated to design and execute ovarian cancer outreach programs for the medical community, including the Survivors Teaching Students program which educated nearly 350 health care students at colleges and universities throughout Minnesota.

Patient and Caregiver Support

MOCA organizes a wide range of educational and support meetings for women and families impacted by ovarian cancer including: two membership meetings, three public education meetings, two ongoing monthly support groups, three young survivors support meetings and one Men of MOCA event. MOCA provides mentoring throughout their MOCA Mentor program and Men of MOCA mentor program. MOCA also provided website resources, critical one on one support to ovarian cancer survivors, families and caregivers via phone, email, and in person at our office 40 hours per week. In addition, MOCA provided Cares Kits full of comfort items for women with ovarian cancer and MOCA Dream Awards for women with ovarian cancer to realize dreams. In 2022 MOCA launched MOCA Walking Groups once a month for ovarian cancer survivors and their loved ones to walk together and connect.

Research

MOCA is a leader in private nonprofit funding for ovarian cancer research. We provide research grants through two separate grantmaking mechanisms. The first is for investigators in Minnesota working on ovarian, primary peritoneal or fallopian tube cancer research. We conduct a competitive grant making process which includes a stringent review by both national expert scientific researchers and consumers to select the most impactful projects. In 2022, MOCA provided eight grants to Minnesota-based researchers for ovarian cancer research projects totaling \$987,000. In 2022, MOCA awarded one grant of \$100,000 to a national researcher for early detection research.

Minnesota Ovarian Cancer Alliance
Notes to the Financial Statements
December 31, 2022 and 2021

Note 1: Summary of Significant Accounting Policies (Continued)

B. Financial Statement Presentation

The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with United States generally accepted accounting principles. Net assets, revenues, expenses, gains and losses are classified based on the existence or absence of donor-imposed restrictions. Accordingly, net assets of the Organization and related changes are classified and reported as follows:

Net Assets without Donor Restriction (Unrestricted)

Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the Organization. These net assets may be used at the discretion of management and the Board of Directors.

Net Assets with Donor Restriction (Restricted)

Net assets subject to stipulations imposed by donors, and grantors. Some donor restrictions are temporary in nature; those restrictions will be met by actions of the Organization or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the funds be maintained in perpetuity. At this time, the Organization has no such perpetually restricted net assets.

C. Use of Estimates

The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts in its financial statements and accompanying notes. Actual results could differ from those estimates.

D. Cash and Cash Equivalents

For purposes of the statement of cash flows, MOCA considers all short-term, highly liquid investments and investments purchased with a maturity of three months or less to be considered cash or cash equivalents. The Organization's cash balances held in bank depositories may exceed federally insured limits at times.

E. Inventory

Inventories consist of various promotional items and are stated at the lower of cost or net realizable value determined on the first-in, first-out basis (FIFO).

F. Investments

Investments consist of mutual funds which are carried at fair value, based on quoted prices in an active market. Investment gains and losses are recognized in the statements of activities in the period in which they occur.

The Organization's investments are exposed to various risks, such as interest rate, credit and overall market volatility. Due to the level of risk associated with certain investments, it is reasonably possible that those changes in the value of investments will occur in the near term and that such changes could be material to the amounts reported in the statements of financial position.

Minnesota Ovarian Cancer Alliance
Notes to the Financial Statements
December 31, 2022 and 2021

Note 1: Summary of Significant Accounting Policies (Continued)

G. Pledges Receivable

Pledges receivables are stated at the amount management expects to collect. Management review receivable balances annually and establishes an allowance based on expected collections. Receivables are written off as a charge to the allowance when, in management’s estimation, it is probable that the receivable is worthless. Management has evaluated receivables and determined that no allowance was necessary at December 31, 2022. Pledges receivable of \$10,000 and \$10,000 are due to be collected in 2023 and 2024, respectively.

H. Property and Equipment

The Organization follows the practice of capitalizing, at cost, all expenditures for property and equipment in excess of \$1,500 with a future benefit of greater than one year. Maintenance and repairs that do not improve or extend the lives of property and equipment are charged to expense as incurred. When assets are sold or retired, their cost and related accumulated depreciation are removed from the accounts and any gain or loss is reported in the statement of activities. Depreciation is charged to activities using the straight-line method over the estimated useful lives of the assets. Estimated useful lives are as follows:

Assets	Useful Lives in Years
Buildings and Improvements	7-39
Office Equipment	3-7
Website	3

Depreciation expense for the years ended December 31, 2022 and 2021 was \$18,195 and \$19,003, respectively.

I. Revenue Recognition

Revenue Recognition is recognized on the accrual basis and generally consists of contributions, special event revenue, in-kind and other income. Special event revenue consists of registrations, sponsorships and other contributions. The exchange element of the special event revenue was approximately \$70,000 and \$75,000 for the years ended December 31, 2022 and 2021, respectively. The portion that is considered to be exchange revenue is recognized as revenue when the performance obligations are met which is the occurrence of the event. There are no contract liabilities associated with this revenue as of December 31, 2022 and 2021.

Contributions are recognized when the donor makes a promise to give to the Organization that is, in substance, unconditional. All donor restricted contributions are reported as increases in net assets with donor restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions. Contributions restricted by donors that have satisfied the donor-imposed restrictions during the year of the contribution are recorded as contributions without donor restrictions.

J. Grants and Awards Payable

Grant commitments are recognized as an expense and liability in the year in which they are authorized by the Organization’s board of directors unless conditions imposed on the grantee have not yet been fulfilled. There are no conditional grants for the years ended December 31, 2022 and 2021. All grants and awards payable as of December 31, 2022 and 2021 are expected to be paid within one year.

Minnesota Ovarian Cancer Alliance
Notes to the Financial Statements
December 31, 2022 and 2021

Note 1: Summary of Significant Accounting Policies (Continued)

K. Functional Expense Allocation

The costs of program and supporting services activities have been summarized on a functional basis in the statement of activities. The statement of functional expense presents the natural classification detail of expenses by function. Most expenses can be directly identified with the program or supporting services to which they relate and are charged accordingly. Indirect expenses are allocated based on employee time and effort, or management’s best estimate.

L. Income Taxes

Minnesota Ovarian Cancer Alliance qualifies as a tax-exempt entity and is exempt from income taxes under Section 501(c)(3) of the Internal Revenue Code and Minnesota Statue 290.05.

M. Advertising

Advertising costs are charged to expense during the year in which they are incurred.

N. New Accounting Pronouncements

In September 2020, the FASB issued ASU No. 2020-07 Not-for-Profit Entities (Topic 958): *Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets*, which is intended to improve the transparency in the reporting of contributed nonfinancial assets, also known as gifts-in-kind, for not-for-profit organizations. This ASU requires not-for-profit organizations to present contributed nonfinancial assets as a separate line item in the statement of activities, apart from contributions of cash or other financial assets. This amendment also requires enhanced disclosures around each category of contributed nonfinancial assets for donor-imposed restrictions, valuation techniques, description of programs or activities in which the assets were used, and if monetized a policy about monetizing rather than utilizing the asset(s). The amendments in this ASU were applied on a retrospective basis and were effective for the Organization in 2022.

O. Subsequent Events

Subsequent events were evaluated through April 17, 2023, which is the date the financial statements were available to be issued.

Note 2: Net assets with Donor Restrictions

Net assets with donor restrictions are restricted for the following purposes as of December 31:

	2022	2021
Research	\$ 22,400	\$ 4,463
Pederson scholarship	4,500	4,500
Lubov fund	7,995	11,000
Colleen Anderson fund	12,680	15,180
Rychwalski fund	8,326	8,326
Total net assets with donor restrictions	\$ 55,901	\$ 43,469

Minnesota Ovarian Cancer Alliance
Notes to the Financial Statements
December 31, 2022 and 2021

Note 2: Net Assets with Donor Restrictions (Continued)

Net assets were released from donor restrictions by incurring expenses satisfying the restricted purpose or by occurrence of other events specified by donors during the years ended 31 are as follows:

	2022	2021
Scholarship fund	\$ 3,005	\$ -
Colleen Anderson fund	2,500	7,500
Research	-	3,172
Net assets released from restrictions	\$ 5,505	\$ 10,672

Note 3: In-Kind Contributions

Donated services are recognized as contributions if they (a) create or enhance nonfinancial assets or (b) require specialized skills, are performed by people with those skills, and would otherwise be purchased by the Organization. Donated materials are valued at market value at the date of donation. The following contribute goods and services were received in 2022 and 2021, respectively:

	2022	2021	Usage in Programs/ Activities	Donor Restriction	Fair Value Techniques
Video Services	\$ 38,788	\$ 22,899	Fundraising	None	Estimated wholesale prices of identical or similar services if purchased in the region
Auction Items	54,115	16,135	Fundraising	None	Estimated wholesale prices of identical or similar products if purchased in the region
Total In-kind Contributions	\$ 92,903	\$ 39,034			

Note 4: Investments Income (Loss)

The investment income (loss) is summarized as follows:

	2022	2021
Net unrealized gains (losses)	\$ (73,912)	\$ 58,393
Interest and dividend income	7,409	6,243
Realized gains	-	752
Total Investment Income (Loss)	\$ (66,503)	\$ 65,388

Minnesota Ovarian Cancer Alliance
Notes to the Financial Statements
December 31, 2022 and 2021

Note 5: Fair Value Measurements

The Organization has categorized its financial instruments, based on the priority of the inputs to the valuation technique, into three-level fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to their fair value measurement of the instrument in its entirety.

Financial assets and liabilities recorded on the statement of activities are categorized based on the inputs to the valuation techniques as follows:

Level 1 – Investments whose values are based on unadjusted quoted prices for identical assets in an active market that the Organization has the ability to access.

Level 2 – Investments and financial liabilities whose values are based on quoted prices in markets that are not active or model inputs that are observable either directly or indirectly for substantially the full term of the asset.

Level 3 – Financial assets are valued using pricing inputs which are unobservable for the asset, inputs that reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the asset.

Following is a description of the Valuation methodologies used for assets measured at fair value. No methodologies were added for the year ended December 31, 2022 and 2021.

Cash and cash equivalents: Valued at cash value

U.S. and International Equities: Valued at the closing price reported in the active market in which the individual securities are traded.

Fixed Income: Valued at the daily price as reported by the fixed income. Fixed Income held by the Organization are open-ended incomes that are registered with the Securities and Exchange Commission.

The following table sets forth by level, within the fair value hierarchy, the Organization's investments at fair value:

	2022			
	Level 1	Level 2	Level 3	Total
Cash and cash equivalents	\$ 38,264	\$ -	\$ -	\$ 38,264
U.S equities	197,998	-	-	197,998
International equities	24,510	-	-	24,510
Fixed income	110,684	-	-	110,684
Total investments	\$ 371,456	\$ -	\$ -	\$ 371,456
	2021			
	Level 1	Level 2	Level 3	Total
Cash and cash equivalents	\$ 34,579	\$ -	\$ -	\$ 34,579
U.S equities	253,660	-	-	253,660
International equities	29,819	-	-	29,819
Fixed income	125,630	-	-	125,630
Total investments	\$ 443,688	\$ -	\$ -	\$ 443,688

Minnesota Ovarian Cancer Alliance
Notes to the Financial Statements
December 31, 2022 and 2021

Note 6: Benefit Plan

The Organization provides a 100% matching contribution up to 3% of participant compensation for all employees. Participant contributions are 100% vested. Organization matching contributions become 100% vested after five years of employment. For vesting purposes, total length of employment will be used to determine the vested percentage of matching contributions. During the years ended December 31, 2022 and 2021, the Organization contributed \$25,169 and \$14,394 to their retirement plan, respectively.

Note 7: Related Party Transactions

Revenue recognized from members of the board of directors totaled \$99,988 and \$81,230 for the years ended December 31, 2022 and 2021, respectively

Note 8: Allocation of Joint Costs

During the year ended December 31, 2022, the Organization conducted activities that included appeals for contributions as part of their Teal Strides event and incurred joint costs of \$17,151. Of these costs \$8,575 was allocated to both fundraising expense and program expense. During the year ended December 31, 2021, the total joint costs were \$11,150. Of these costs, \$5,575 was allocated to both fundraising expense and program expense.

Note 9: Liquidity and Availability of Financial Assets

The Organization has the following assets available for general expenditures within one year at December 31:

	2022	2021
Cash and cash equivalents	\$ 876,089	\$ 1,278,105
Account receivable	3,005	2,500
Pledge receivable, current	10,000	-
Investments	371,456	443,688
Total Financial Assets	1,260,550	1,724,293
Less: Donor Restrictions amounts unavailable for general expenditure within one year	(55,901)	(35,006)
Total financial assets available within one year	\$ 1,204,649	\$ 1,689,287

The Organization has an operating Reserve Policy to maintain an operating reserve of 25% to 50% of the following year's budgeted operating expenses. The actual amount of reserve is approved by the Board of Directors as a part of the budget process. The excess of funds over the operating reserve is then released to research funds to be awarded in the next budget cycle.